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Abstract
Background: Congenital diaphragmatic hernia (CDH) is a severe congenital anomaly of the diaphragm resulting in
pulmonary hypoplasia and pulmonary hypertension. It is associated with a high risk of mortality and pulmonary
morbidity. Previous retrospective studies have reported high frequency oscillatory ventilation (HFO) to reduce
pulmonary morbidity in infants with CDH, while others indicated HFO to be associated with worse outcome. We
therefore aimed to develop a randomized controlled trial to compare initial ventilatory treatment with high-
frequency oscillation and conventional ventilation in infants with CDH.
Methods/design: This trial is designed as a multicentre trial in which 400 infants (200 in each arm) will be
included. Primary outcome measures are BPD, described as oxygen dependency by day 28 according to the
definition of Jobe and Bancalari, and/or mortality by day 28. All liveborn infants with CDH born at a gestational
age of over 34 weeks and no other severe congenital anomalies are eligible for inclusion. Parental informed
consent is asked antenatally and the allocated ventilation mode starts within two hours after birth. Laboratory
samples of blood, urine and tracheal aspirate are taken at the first day of life, day 3, day 7, day 14 and day 28 to
evaluate laboratory markers for ventilator-induced lung injury and pulmonary hypertension.
Discussion: To date, randomized clinical trials are lacking in the field of CDH. The VICI-trial, as the first randomized
clinical trial in the field of CDH, may provide further insight in ventilation strategies in CDH patient. This may
hopefully prevent mortality and morbidity.
Trial registration: Netherlands Trial Register (NTR): NTR1310
Background
Congenital diaphragmatic hernia (CDH) is a severe con-
genital anomaly of the diaphragm, which occurs in
approximately one in 3000 live births [1]. In CDH, the
diaphragmatic defect allows abdominal organs to herni-
ate into the chest cavity. As a consequence, underdeve-
lopment of the lungs and abnormal pulmonary
vasculature growth may occur, resulting in pulmonary
hypoplasia and pulmonary hypertension [2,3].
Children with CDH mostly present with immediate
cardiorespiratory distress during the first hours of life.
The initial therapy for these children is mechanical ven-
tilation and cardiorespiratory stabilization in support of
optimal management of the pulmonary hypoplasia and
pulmonary hypertension [4]. Thereafter, surgical repair
of the diaphragmatic defect is indicated [4]. Although
many advances in treatment for CDH patients have
been made throughout the years, CDH remains a life-
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threatening condition with a reported mortality of 20-
70%, depending on case selection [5].
Survivors of CDH are at risk of developing secondary
morbidity, such as gastro-intestinal, neurodevelopmental
and pulmonary sequelae. Throughout infancy and child-
hood, a broad spectrum of pulmonary morbidity may
occur, such as bronchopulmonary dysplasia (BPD), per-
sistent pulmonary hypertension, recurrent respiratory
tract infections and asthmatic symptoms [6]. BPD is
characterized by disturbances of the normal alveolariza-
tion. Ventilator-induced lung injury, oxygen toxicity,
pulmonary inflammatory responses, and severe pulmon-
ary hypertension predispose infants with CDH to
develop BPD [7,8]. A recent report of the CDH Registry
reported the prevalence of BPD to be 41% in infants
with CDH [9]. About half of the CDH survivors with
BPD are reported to have moderate to severe BPD [10].
Moreover, lung function anomalies are often present in
these patients [11-14].
Optimizing ventilation strategies in patients with CDH
may help to prevent chronic respiratory disease. How-
ever, evidence-based standardized treatment protocols
based are lacking in the field of CDH. Consequently, ven-
tilation strategies may differ between centres and ventila-
tory support is often based upon expert opinion [7]. To
date, conventional ventilation is the most widely used
initial ventilation mode in newborns with CDH, while in
many institutions high frequency oscillatory ventilation
(HFO) is used as rescue therapy. In some centres, how-
ever, HFO is used as the initial ventilation mode.
HFO achieves adequate gas exchange by an oscillatory
pump, which combines very high respiratory rates and
low tidal volumes. HFO may improve gas exchange,
promote uniform lung inflation, reduce barotrauma, and
decrease the presence of inflammatory mediators
[7,15-18]. HFO has been used in preterm infants with
respiratory distress syndrome, either as an elective venti-
lation strategy or as a rescue therapy [16]. A Cochrane
review, on the use of elective HFO compared to CMV
in preterm infants, found a borderline significant reduc-
tion in the rate of chronic lung disease with the use of
HFO [16]. A second Cochrane review described the use
of HFO as a rescue therapy in term and near term
infants with severe pulmonary dysfunction. Only one
trial compared these two ventilation strategies prospec-
tively, resulting in no significant difference in outcome,
need for extracorporeal membrane oxygenation
(ECMO), or complications [15,19].
In infants with CDH, retrospective and observational
studies reported improved survival and a lower inci-
dence of chronic lung disease with elective use of HFO
[20-25]. HFO was reported to provide better oxygena-
tion and higher MAP without increasing the incidence
of barotraumas [20,21]. In one study, the use of HFO
avoided hyperventilation as well as the need for ECMO
[17]. Moreover, inhaled nitric oxide was documented to
result in better gas exchange following recruitment of
the lungs by HFO [26]. On the contrary, HFO may
cause lung hyperinflation in some patients, which may
induce higher alveolar and mean airway pressures [21].
This may result in an increased risk of pulmonary baro-
trauma and hemodynamic instability [21]. A recent
study by the CDH Registry reported HFO as initial ven-
tilation mode to be associated with an increased rate of
mortality and BPD [9]. In this study, it is speculated
that infants who received initially HFO were more
severely ill from the start [9].
Conclusively, chronic pulmonary morbidity and high
mortality rates are major problems in infants with CDH.
Several retrospective and observational studies have
reported that mechanical ventilation strategies may have
an impact on outcome and pulmonary morbidity in
CDH patients. Therefore, we aimed to develop a rando-
mized controlled trial to compare initial ventilatory
treatment with HFO and conventional ventilation in
infants with CDH. The acronym VICI is deducted from
the words: HFO versus conventional Ventilation in
Infants with Congenital diaphragmatic hernia: an Inter-
national randomised clinical trial. In Latin vici means ‘I
have conquered’ which refers to our patients with CDH
which are very vulnerable and ill and sometimes have to
struggle to survive.
The primary objective of this trial is to determine if
there is a difference in the incidence of BPD and/or
death within the first 28 days of life between newborns
with congenital diaphragmatic hernia treated with high
frequency oscillatory ventilation (HFO) and those trea-
ted with conventional mechanical ventilation (CMV) as
initial ventilation mode. Secondarily, we also aim to
compare the severity of BPD, ventilator-induced lung
injury and pulmonary hypertension by using clinical and
laboratory parameters.
Methods/Design
This study is designed as a prospective, randomized
controlled multicentre trial. All participating centres are
member of the CDH-EURO Consortium. This is a colla-
boration between European tertiary centres, who have
an expertise in the field of CDH. The CDH-EURO con-
sortium was started in 2006 and aims at cooperation
between centres, enhancement of research in the field of
CDH and development of standardized evidence-based
treatment protocols.
Outcome measures
The primary outcome measure is BPD and/or death
within the first 28 days of life. Secondary outcome para-
meters are overall mortality, severity of BPD, number of
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days on the ventilator, number of treatment failures,
ventilation-induced lung injury and pulmonary hyper-
tension according to clinical and laboratory parameters
and need for ECMO (only for ECMO centres). BPD is
defined as oxygen dependency at day 28, according to
the definition of Jobe and Bancalari [27]. The severity of
BPD is also defined according to this definition (see
table 1).
Inclusion and exclusion criteria
The study population consists of all infants antenatally
diagnosed with CDH born at one of the participating
centres.
Exclusion criteria are:
• Birth before a gestational age of 34 weeks
• Severe chromosomal anomalies, like trisomy 18 or
trisomy 13, which may imply a decision to stop or
not to start life-saving medical treatment
• Severe cardiac anomalies, expected to need correc-
tive surgery in the first 60 days of life (such as trans-
position of the great arteries, truncus arteriosus or
double outlet right ventricle)
• Renal anomalies associated with oligohydramnios
• Severe orthopaedic and skeletal deformities, which
are likely to influence thoracic, and/or lung develop-
ment (such as chest wall deformities and spine
anomalies)
• Severe anomalies of the central nervous system
Statistical analysis
We estimated that a total of 400 newborns can be
included within a period of three years. In a previous
study of the CDH study group, the incidence of BPD
and/or death within the first 28 days of life is reported
to be about 50% [9]. Assuming a difference of 15% in
BPD and/or death within the first 28 days between both
treatment groups, 186 patients are required per arm for
a power of 80% at two-sided alpha is 0.05. To allow for
some non-evaluable patients and dropouts, 200 patients
per group will be included. To achieve equal distribution
of the two ventilation modes among the participants,
block randomization stratified per centre will be carried
out. The data-analysis will be carried out at the Erasmus
MC, Rotterdam. An intention-to-treat analysis will be
performed. A p-value (two-sided) < 0.05 will be consid-
ered significant in all analyses.
The primary endpoint will be evaluated using multiple
logistic regression analysis taking account of: centre,
lung-to-head ratio, position of the liver (intra-abdominal
or intra-thoracic) and the side of the defect (left, right
or central). A subgroup analysis will be carried out in
operated infants to evaluate the defect size, according to
the CDH study group defect size scale (http://www.
cdhsg.net).
The secondary endpoints will be evaluated by using
the following statistical tests. Overall mortality in the
first year of life will be analysed by Kaplan-Meier curves
and Log rank tests. The chi-square test will be used to
analyse number of treatment failures, presence of pul-
monary hypertension according to echocardiographic
parameters, requirement of medication at discharge and
during the first year of life, and need for ECMO therapy
(in ECMO centres). The Mann-Whitney test is used to
evaluate the severity of chronic lung disease, number of
days on the ventilator and the fraction of days with
required medical treatment for pulmonary hypertension
during the hospital admission. In the evaluation of the
severity of chronic lung disease and the number of days
on the ventilator, deaths are counted as worst outcome
according to the intention-to-treat principle. Repeated
measures ANOVA is used to evaluate levels of labora-
tory markers for ventilator-induced lung injury or pul-
monary hypertension and pulmonary function at the age
of six and twelve months. This analysis allows for miss-
ing data at different time points and is considered as the
optimal way for evaluation of longitudinal data.
All the above-mentioned analyses will allow for centre
by stratification.
Table 1 definition of BPD according to Jobe and Bancalari
Gestational age < 32 weeks > 32 weeks
Time point
assessment
36 wks PMA* or DC** to home, whichever comes first > 28 days but < 56 days of life or discharge to home,
whichever comes first
Treatment with oxygen > 21% for at least 28 days PLUS
Mild BPD On room air at 36 wks PMA or at DC, whichever comes first On room air at day 56 postnatal age or DC, whichever comes
first
Moderate BPD < 30% O2 at 36 wks PMA or DC, whichever comes first < 30% O2 at 56 d of life or DC whichever comes first
Severe BPD ≥ 30% O2 and/or pos. pressure at 36 wks PMA or DC
whichever comes first
≥ 30% O2 and/or pos. pressure at 56 d of life or DC
whichever comes first
*PMA = post-menstrual age
**DC = discharge
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Study procedures
Parental informed consent will be obtained antenatally
to enhance quick randomization. Following antenatal
diagnosis, the parents are to be counselled and will
receive information about the study, including a patient
information letter and an informed consent form. If
both parents decide to participate in the study, as soon
as possible after birth central randomization will take
place by the treating physician using a website. This way
concealed allocation is guaranteed. Within two hours
after delivery, the allocated ventilatory treatment has to
be started.
The patient receives the allocated ventilation treat-
ment during the entire admission period on the inten-
sive care unit. During surgery, the child preferably
remains on the allocated ventilation type, provided the
treating surgeon agrees. Should the surgeon opt for the
other ventilation mode, the patient is switched to the
allocated ventilation treatment again after surgery. If the
patient has to be re-intubated within the first 60 days
after the start of the allocated treatment, the patient
receives the allocated treatment again. Patients are
observed up to day 60 after birth or until discharge
whichever comes first. In Figure 1, an overview of the
study procedures is given.
Standardized treatment and ventilation settings
All infants participating in the VICI-trial are treated
according to the same standardized treatment protocol
which has been published recently [4]. This protocol of
standard practice was decided upon available evidence
and consensus between the participating centres.
After birth, all infants are immediately intubated. In
general, our goals are to achieve preductal saturations
between 85 and 95%, postductal saturation levels above
70% and arterial CO2 levels between 45-60 mm Hg (per-
missive hypercapnia). Conventional mechanical ventila-
tion is provided by a neonatal ventilator capable of
positive pressure ventilation or triggered modes (Babylog
ventilator, Dräger Medical, Germany). High frequency
oscillatory ventilation (HFO) is provided by a high fre-
quency oscillatory ventilator (Sensormedics 3100A/B
HFO Ventilator, Viasys Healthcare, USA).
If the allocated treatment is conventional ventilation,
the following settings are used: a peak inspiratory
pressure (PIP) of 20-25 cm H2O, a positive end-expira-
tory pressure (PEEP) of 2-5 cm H2O and a frequency of
40-60 per minute. In case of HFO, the settings are: a
mean airway pressure (MAP) of 13 to 17 cm H2O, a fre-
quency of 10 Hz, an amplitude (Δp, cm H2O) of 30 to
50 obtaining chest vibrations, and an inspiration/expira-
tion rate (I:E) of 1:1.
According to our standardized treatment protocol, a
chest radiograph is made as soon as possible after birth
to assess the initial condition and is repeated guided on
the patient’s condition. In case of HFOV, a chest radio-
graph is also made after this ventilation mode is started
to confirm that the lungs are not overinflated, as defined
by a contralateral lung expansion of over 8 ribs. Also,
echocardiography is performed within the first 24 hours
after birth to assess pulmonary arterial diameter and
right heart function. In all patients, a chest radiograph
and echocardiography are repeated at day 28.
Weaning from conventional ventilation is done by
means of decreasing PIP. Frequency and/or the PIP-
PEEP were modified to achieve PaCO2 levels above 45
mmHg. In case of HFOV, Δp was decreased if the
paCO2 was below 45 mmHg and FiO2 was decreased if
preductal saturation levels were above 95%.
In case of hypovolemia and/or cardiogenic shock, sal-
ine fluid therapy is started (10 to 20 ml/kg of NaCl 0.9%
up to three times during the first one to two hours),
which is followed by inotropic therapy if necessary. At
an oxygenation index of 20 or higher and/or a pre- and
postductal saturation difference of 10% or more, 10-20
ppm iNO is given for at least one hour. Intravenous
prostacyclin or prostaglandin E1 may be considered in
case of no response to iNO. Sildenafil may be consid-
ered in the chronic phase of pulmonary hypertension.
Surgery is performed if the patient is physiologically
stabile according to the criteria described in our proto-
col [4]. No routine paralysis is used.
Treatment failure
In case of one or more failure criteria, the allocated ven-
tilatory treatment may be switched. Also, an ECMO
procedure may be started in centres where ECMO is
available. After the ECMO-procedure has ended, the
patient preferably receives the initial allocated ventila-
tion mode. Because an intention-to-treat analysis will be
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Figure 1 Overview study procedures.
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performed, data from these patients are stored and ana-
lysed the same way as data from patients in whom no
switching of ventilation mode or ECMO procedure took
place.
The following failure criteria are applicable to the
study patients:
• Inability to maintain preductal saturations above
85% (± 7 kPa or 52 mmHg) or postductal satura-
tions above 70% (± 5.3 kPa or 40 mmHg)
• Increase in CO2 > 65 torr or mmHg (8.5 kPa)
despite optimalization of ventilatory management
• PIP > 28 cm H2O or MAP > 17 cm H2O
• Inadequate oxygen delivery with metabolic acidosis
defined as lactate ≥ 5 mmol/l and pH < 7.20
• Hypotension resistant to fluid therapy and ade-
quate inotropic support, resulting in a urine output
< 0.5 ml/kg/hour
• Oxygenation index consistently ≥ 40
Laboratory analyses
During the study, blood, urine and tracheal samples are
collected. Separate parental informed consent is asked
for taking, analysing and storing these samples.
Blood, urine and tracheal samples are taken within the
first 2 hours of life and on days 3, 7, 14 and 28. Blood
sampling is only done if a central or peripheral line is
present and in combination with routine laboratory
measurements. Urine sampling is only done if the
patient has a urine catheter. Sampling of tracheal aspi-
rates is only done during routine suctioning. In that
way, sampling of laboratory markers are of minimal bur-
den for the patient.
Blood samples
Blood markers are determined by immuno-assay analysis
and are necessary support evidence of chronic lung dis-
ease and to further evaluate its severity [28-32].
The following laboratory markers are measured:
• Markers for inflammation and pulmonary vascular
endothelial dysfunction and pulmonary hypertension
(intercellular adhesion molecule (ICAM), vascular
cell adhesion molecule (VCAM), sP- and sE-selec-
tine, pro-brain natriuretic peptide (Pro-BNP), vascu-
lar endothelial growth factor (VEGF), von
Willebrand factor, thrombomodulin, factor VIII and
Asymmetric Dimethylarginine (ADMA)
• Markers for the nitroxide pathway (nitrate and
nitrite)
Urine samples
Two urine samples from an 8-hour urine collection are
taken to measure desmosine, an elastolytic degradation
product of elastin. It gives an indication of the degrada-
tion of lung elastic fibres in ventilated neonates. One
sample of 20 ml containing 0.2% boric acid and one sam-
ple of 10 ml will be stored at -20 degrees Celsius. Desmo-
sine will be measured by mass-spectrometry, a highly
sensitive way of measuring this laboratory marker [33,34].
Tracheal aspirate
Protein profiling by proteomics are used for identifying
specific groups of proteins, which are involved in the
pathogenesis of chronic lung disease. During routine
tracheal suctioning, flushing with 0.5-1.0 ml saline is
performed according to standard practice. The tracheal
aspirates are centrifuged for 10 minutes at 3000 rpm
and are stored at -80 degrees Celsius [35,36].
Follow-up
At all participating centres, routine follow-up takes place
at the age of 6 months, 12 months, 24 months, 5 years,
8 years, 12 years and 18 years in all patients with CDH,
including participants of the VICI-trial. During follow-
up visits, routine physical examination and additional
testing (e.g. lung function tests or developmental tests)
take place. For the purpose of this study, parents com-
plete a patient diary card on a daily basis for one month
at the age of six and twelve months. By using this diary
card information about whether their child coughed,
wheezed and/or needed medication is collected. This
gives a quantitative assessment of morbidity.
In a subgroup of patients born at the Erasmus Medical
Centre and King’s College Hospital, lung function tests
are performed at the age of six and twelve months. Only
these two centres have the equipment and expertise to
measure lung function in children below the age of one.
At King’s College, FRC (functional residual capacity)
and LCI (lung clearance index) are measured by using
helium gas dilution. The LCI is the cumulative expired
volume required to clear an inert gas from the lungs,
divided by the FRC. Also, lung function tests are per-
formed before and after bronchodilation at this centre.
Therefore, a bronchodilator is administered by a face
mask and a spacer. At the Erasmus Medical Centre, the
FRC is determined by plethysmographic measurements
and the LCI is defined by SF6 measurements.
Since the methods of lung function measurements dif-
fer between the two centres, these measurements will be
analysed separately for both centres.
Safety reporting
An adverse event or complication is defined as any
undesirable occurrence in a patient. Mortality is
regarded a serious adverse event. Adverse events or
complications are reported to the study coordinator
within 24 hours. Thereafter, the study coordinator
informs the data safety monitoring board, who monitors
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the incidence of mortality on a continuous base. If at
some point a large difference in mortality between the
two treatment groups is noticed, the data safety moni-
toring board may recommend ending the study.
Data collection
Demographic and neonatal characteristics as well as
data on the clinical course and treatment of all patients
will be collected in a central database in Rotterdam.
Corporeal material collected during the study is stored
at the local centres.
Since it should be impossible to identify a specific
patient, data are sealed by a code and a patient number
replaces personal data. All centres keep a logbook of the
number of eligible non-participants, including the rea-
sons for not participating.
Patient data are stored during the study and for fifteen
years after the study has ended. If the parents consent,
corporeal material is also stored for fifteen years after
the study has ended. This material may be used in
future for a study with the same research aims.
Ethical approval
The first of October 2008, this study has been given
approval by the medical ethics committee of the Eras-
musMC Rotterdam. Thereafter, the local medical ethics
committees of eleven participating centres gave their
approval. In one centre, ethical approval is still being
sought. Once a year, a summary of the trial’s progress is
send to the medical ethics committee of the ErasmusMC,
Rotterdam, the Netherlands. Information is provided on
the numbers of subjects included, (serious) adverse
events, other problems and amendments. New participat-
ing centres are still included. We will continue recruiting
patients for our trial until we reached the number of 400
participants. Our goal is to have this amount of patients
included by the first of October 2013.
Discussion
Congenital diaphragmatic hernia (CDH) is associated
with a high risk pulmonary morbidity [6]. Several pre-
vious studies have reported a wide range of pulmonary
problems throughout childhood in these patients [6]. A
recent study of our group in collaboration with the
CDH Registry reported a 41% prevalence of bronchopul-
monary dysplasia (BPD) in survivors of CDH [9]. This
study reported the initial ventilation mode to be possibly
associated with BPD in these patients. This formed the
rationale for our study, which aims at comparing HFO
and conventional ventilation as initial ventilation modes
in infants with CDH.
Our study is the first randomized clinical trial in the
field of CDH. Previous studies were retrospective or
observational reports, mostly from single centres.
Moreover, progress in CDH research is hampered due
to small numbers of patients and lack of evidence-based
treatment strategies. Cooperation between centres is
therefore highly important to enhance research,
exchange knowledge and compare data in larger groups
of patients. The CDH Study Group is an example of a
worldwide network which has established a large data-
base on CDH patients. To date, the CDH Study Group
has published numerous reports in the field of CDH,
which contain valuable information on survival, treat-
ment strategies and morbidity in infants with CDH.
Another example is the CDH-EURO consortium, a Eur-
opean collaboration between tertiary centres with an
expertise in treatment of CDH, which also initiated the
VICI-trial. The consortium also developed a recently
published standardized treatment protocol [4]. This
treatment protocol makes valuable comparison of
patient data possible, since all CDH patients, including
the VICI-trial patients, born in these centres are treated
according to this protocol.
HFO and conventional ventilation are both safe, effec-
tive and widely used strategies to ventilate infants with
respiratory distress. Although observational and retro-
spective studies have suggested that HFO may improve
survival and pulmonary outcome in infants with CDH,
no prospective randomized controlled trials have been
carried out to compare initial ventilation strategies in
these patients. Therefore, no specific conclusions about
certain benefits or disadvantages of either HFO or CMV
can be made.
As the first randomized clinical trial in CDH infants,
the VICI-trial will provide a clearer view on ventilatory
treatment strategies and possible prevention of mortality
and morbidity. Still, there are many questions left in the
field of CDH and clinical trials are highly needed to
improve care and establish standardized treatment.
Cooperative networks between centres, such as the
CDH-EURO consortium, play a major role in this.
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